CP
ACRS icon

CenterBook Partners’s Aclaris Therapeutics ACRS Stock Holding History

CenterBook Partners’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$250K Buy
+66,598
New +$225K 0.01% 595

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

CenterBook Partners's ACRS Position: Q1 2026 in Review

CenterBook Partners opened a new position in Aclaris Therapeutics (ACRS) in Q1 2026: 66,598 shares worth $250K. The stake represents 0.01% of the portfolio and ranks #595 among its holdings.

136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • CenterBook Partners held 66,598 shares of Aclaris Therapeutics worth $250K as of Q1 2026.
  • Aclaris Therapeutics was a new CenterBook Partners position in Q1 2026.
  • Aclaris Therapeutics made up 0.01% of CenterBook Partners's portfolio in Q1 2026, its #595 holding.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on CenterBook Partners's 13F filing for Q1 2026, filed 5 May 2026.